

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	1756623
<b>Application Number:</b>	10538226
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	9406
<b>Title of Invention:</b>	Administration of dendritic cells partially matured in vitro for the treatment of tumors
<b>First Named Inventor/Applicant Name:</b>	Marnix L Bosch
<b>Customer Number:</b>	20350
<b>Filer:</b>	Brian W. Poor/Jennifer Smolen
<b>Filer Authorized By:</b>	Brian W. Poor
<b>Attorney Docket Number:</b>	020093-004010US
<b>Receipt Date:</b>	09-MAY-2007
<b>Filing Date:</b>	06-JUN-2005
<b>Time Stamp:</b>	13:02:25
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part /.zip	Pages (if appl.)
1	Foreign Reference	WO_00_47719.pdf	2056206	no	56

**Warnings:**

<b>Information:</b>					
2	Foreign Reference	WO_03_010292.pdf	2613368	no	49
<b>Warnings:</b>					
<b>Information:</b>					
3	Foreign Reference	WO_04_076651.pdf	2288803	no	49
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	Candido_CancerRes_2001.pdf	957191	no	9
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	Chakraborty_ClinImmunol_1999.pdf	1369128	no	11
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	Kadowaki_JImmunol_2001.pdf	456787	no	5
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	Kikuchi_Blood_2000.pdf	901574	no	9
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	Kurts_JExpMed_1996.pdf	760294	no	8
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	Kurts_JExpMed_1997.pdf	608678	no	7
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	Lanzavecchia_Haematologica_1999.pdf	479675	no	3
<b>Warnings:</b>					

<b>Information:</b>					
11	NPL Documents	Melero_GeneTherapy_1999.pdf	674287	no	6
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	Nestle_Oncogene_2000.pdf	538421	no	7
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	Nikitina_IntJCancer_2001.pdf	3416201	no	9
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	Nishioka_CancerRes_1999.pdf	767085	no	7
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	ShortmanandHeath_NatureImmunol_2001.pdf	3554186	no	2
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	Tanaka_IntJCancer_2002.pdf	4350253	no	6
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	Tjoa_CA_A_CancerJClinic_1999.pdf	733219	no	12
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	Tong_CancerRes_2001.pdf	643722	no	6
<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	Trimble_ProcAmAssoc_2002.pdf	157545	no	1
<b>Warnings:</b>					

<b>Information:</b>					
20	NPL Documents	Triozzi_Cancer_2000.pdf	6429592	no	10
<b>Warnings:</b>					
<b>Information:</b>					
21	NPL Documents	Tsuji_InfectImmun_2000.pdf	605402	no	8
<b>Warnings:</b>					
<b>Information:</b>					
22	Foreign Reference	PCT_ISR.pdf	148878	no	3
<b>Warnings:</b>					
<b>Information:</b>					
23	Foreign Reference	Supp_EPO_Search.pdf	94675	no	3
<b>Warnings:</b>					
<b>Information:</b>					
24	Information Disclosure Statement (IDS) Filed	IDS_2007_05_09.PDF	229896	no	5
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
<b>Total Files Size (in bytes):</b>			34835066		
<p><b>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</b></p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>          If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>          If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b>          If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					